BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 37385460)

  • 1. Abnormalities on baseline chest imaging are risk factors for immune checkpoint inhibitor associated pneumonitis.
    Stahlbaum D; Jablonski R; Strek ME; Bestvina CM; Polley MY; Reid P
    Respir Med; 2023 Oct; 217():107330. PubMed ID: 37385460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association Between Pretreatment Chest Imaging and Immune Checkpoint Inhibitor Pneumonitis Among Patients With Lung Cancer.
    Wong A; Riley M; Zhao S; Zimmer J; Viveiros M; Wang JG; Esguerra V; Li M; Lopez G; Kendra K; Carbone DP; He K; Alahmadi A; Kaufman J; Memmott RM; Shields PG; Brownstein J; Haglund K; Welliver M; Otterson GA; Presley CJ; Wei L; Owen DH; Ho K
    J Natl Compr Canc Netw; 2023 Nov; 21(11):1164-1171.e5. PubMed ID: 37935100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between pre-treatment chest imaging and pulmonary function abnormalities and immune checkpoint inhibitor pneumonitis.
    Wong A; Riley M; Zhao S; Wang JG; Esguerra V; Li M; Lopez G; Otterson GA; Kendra K; Presley CJ; Wei L; Owen DH; Ho K
    Cancer Immunol Immunother; 2023 Jun; 72(6):1727-1735. PubMed ID: 36640189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Baseline Interstitial Lung Abnormalities on Pneumonitis Risk in Patients Receiving Immune Checkpoint Inhibitors for Non-Small-Cell Lung Cancer.
    Petranovic M; McDermott S; Mercaldo S; Little BP; Graur A; Huang K; Fintelmann FJ; Digumarthy SR; Gainor JF
    Clin Lung Cancer; 2023 Dec; 24(8):682-688.e5. PubMed ID: 37758549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Findings on Chest CT Performed in the Emergency Department in Patients Receiving Immune Checkpoint Inhibitor Therapy: Single-Institution 8-Year Experience in 136 Patients.
    Smith DA; Radzinsky E; Tirumani SH; Guler E; Petraszko A; Kikano E; Hoimes CJ; Ramaiya NH
    AJR Am J Roentgenol; 2021 Sep; 217(3):613-622. PubMed ID: 33295801
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical and radiological features of immune checkpoint inhibitor-related pneumonitis in lung cancer and non-lung cancers.
    Nobashi TW; Nishimoto Y; Kawata Y; Yutani H; Nakamura M; Tsuji Y; Yoshida A; Sugimoto A; Yamamoto T; Alam IS; Noma S
    Br J Radiol; 2020 Nov; 93(1115):20200409. PubMed ID: 32783627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome and risk factor of immune-related adverse events and pneumonitis in patients with advanced or postoperative recurrent non-small cell lung cancer treated with immune checkpoint inhibitors.
    Isono T; Kagiyama N; Takano K; Hosoda C; Nishida T; Kawate E; Kobayashi Y; Ishiguro T; Takaku Y; Kurashima K; Yanagisawa T; Takayanagi N
    Thorac Cancer; 2021 Jan; 12(2):153-164. PubMed ID: 33201587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive Pneumonitis Profile of Thoracic Radiotherapy Followed by Immune Checkpoint Inhibitor and Risk Factors for Radiation Recall Pneumonitis in Lung Cancer.
    Lu X; Wang J; Zhang T; Zhou Z; Deng L; Wang X; Wang W; Liu W; Tang W; Wang Z; Wang J; Jiang W; Bi N; Wang L
    Front Immunol; 2022; 13():918787. PubMed ID: 35795657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitors.
    Chu X; Zhao J; Zhou J; Zhou F; Jiang T; Jiang S; Sun X; You X; Wu F; Ren S; Zhou C; Su C
    Lung Cancer; 2020 Dec; 150():76-82. PubMed ID: 33080551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiation Versus Immune Checkpoint Inhibitor Associated Pneumonitis: Distinct Radiologic Morphologies.
    Chen X; Sheikh K; Nakajima E; Lin CT; Lee J; Hu C; Hales RK; Forde PM; Naidoo J; Voong KR
    Oncologist; 2021 Oct; 26(10):e1822-e1832. PubMed ID: 34251728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune checkpoint inhibitor-related chronic pneumonitis: a case report and literature review.
    Yuan-Di Wang ; Yuan S; Wen C; Ji Z; Xiang B; Wang B; Zhang Z
    Immunotherapy; 2023 Oct; 15(14):1117-1123. PubMed ID: 37431609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune Checkpoint Inhibitor-Related Pneumonitis in Lung Cancer Patients with Interstitial Lung Disease: Significance of Radiological Pleuroparenchymal Fibroelastosis.
    Osaki M; Arai T; Sumikawa H; Takimoto T; Takeuchi N; Tamiya A; Okishio K; Inoue Y
    Oncology; 2023; 101(5):303-312. PubMed ID: 36689929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brief report: inhaled corticosteroid use and the risk of checkpoint inhibitor pneumonitis in patients with advanced cancer.
    Li M; Spakowicz D; Zhao S; Patel SH; Johns A; Grogan M; Miah A; Husain M; He K; Bertino EM; Shields PG; Wei L; Carbone DP; Otterson GA; Presley CJ; Owen DH
    Cancer Immunol Immunother; 2020 Nov; 69(11):2403-2408. PubMed ID: 32728772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pneumonitis after immune checkpoint inhibitor therapies in patients with acute myeloid leukemia: A retrospective cohort study.
    Sheshadri A; Goizueta AA; Shannon VR; London D; Garcia-Manero G; Kantarjian HM; Ravandi-Kashani F; Kadia TM; Konopleva MY; DiNardo CD; Pierce S; Zarifa A; Albittar AA; Zhong LL; Akhmedzhanov FO; Arain MH; Alfayez M; Alotaibi A; Altan M; Naing A; Mendoza TR; Godoy MCB; Shroff G; Kim ST; Faiz SA; Kontoyiannis DP; Khawaja F; Jennings K; Daver NG
    Cancer; 2022 Jul; 128(14):2736-2745. PubMed ID: 35452134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characteristics, incidence, and risk factors of immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer.
    Cho JY; Kim J; Lee JS; Kim YJ; Kim SH; Lee YJ; Cho YJ; Yoon HI; Lee JH; Lee CT; Park JS
    Lung Cancer; 2018 Nov; 125():150-156. PubMed ID: 30429014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Preexisting Interstitial Lung Abnormalities With Immune Checkpoint Inhibitor-Induced Interstitial Lung Disease Among Patients With Nonlung Cancers.
    Shimoji K; Masuda T; Yamaguchi K; Sakamoto S; Horimasu Y; Nakashima T; Miyamoto S; Iwamoto H; Fujitaka K; Hamada H; Takeno S; Hide M; Teishima J; Ohdan H; Hattori N
    JAMA Netw Open; 2020 Nov; 3(11):e2022906. PubMed ID: 33180128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differentiation between immune checkpoint inhibitor-related and radiation pneumonitis in lung cancer by CT radiomics and machine learning.
    Cheng J; Pan Y; Huang W; Huang K; Cui Y; Hong W; Wang L; Ni D; Tan P
    Med Phys; 2022 Mar; 49(3):1547-1558. PubMed ID: 35026041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune check-point inhibitor-related pneumonitis: acute lung injury with rapid progression and organising pneumonia with less severe clinical disease.
    Imran S; Golden A; Feinstein M; Plodkowski A; Bodd F; Rekhtman N; Travis WD; Stover DE; Sauter JL
    Histopathology; 2022 Dec; 81(6):724-731. PubMed ID: 35775853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiation and immune checkpoint inhibitor-mediated pneumonitis risk stratification in patients with locally advanced non-small cell lung cancer: role of functional lung radiomics?
    Thomas HMT; Hippe DS; Forouzannezhad P; Sasidharan BK; Kinahan PE; Miyaoka RS; Vesselle HJ; Rengan R; Zeng J; Bowen SR
    Discov Oncol; 2022 Sep; 13(1):85. PubMed ID: 36048266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical insights on outcomes of corticosteroid administration in immune checkpoint inhibitor-induced pneumonitis by retrospective case series analysis.
    Park C; Keam B; Yoon SH; Ock CY; Choi SM; Kim M; Park YS; Kim TM; Oh DY; Kim DW; Kim YW; Heo DS; Bang YJ
    ESMO Open; 2019; 4(6):e000575. PubMed ID: 31803501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.